PDF Cover

Golimumab Market

The market for Golimumab was estimated at $16.8 billion in 2024; it is anticipated to increase to $21.6 billion by 2030, with projections indicating growth to around $26.7 billion by 2035.

Report ID:DS1802080
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Golimumab
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Golimumab Market Outlook

Revenue, 2024

$16.8B

Forecast, 2034

$25.6B

CAGR, 2025 - 2034

4.3%

The Golimumab industry revenue is expected to be around $17.5 billion in 2025 and expected to showcase growth with 4.3% CAGR between 2025 and 2034. Building on this growth trajectory, the golimumab market continues to maintain strong clinical and commercial relevance within the global biologics and immunology therapeutics landscape. Demand is largely driven by the rising prevalence of chronic autoimmune diseases such as rheumatoid arthritis, ulcerative colitis, and psoriatic arthritis, which require long-term biologic therapy. Increasing diagnosis rates, improved access to specialty healthcare, and expanding reimbursement frameworks in developed markets are supporting steady treatment adoption. In addition, the growing shift toward targeted biologic therapies is encouraging healthcare providers to adopt tumor necrosis factor inhibitors for patients who do not respond adequately to conventional disease-modifying drugs. Pharmaceutical companies are also strengthening distribution channels and patient-support programs to improve treatment accessibility. Emerging healthcare markets are witnessing gradual adoption as hospitals and specialty clinics expand biologic therapy capabilities and government healthcare spending on autoimmune disease management increases.

Golimumab is a monoclonal antibody that targets tumor necrosis factor alpha, a key inflammatory cytokine involved in several autoimmune disorders. By inhibiting this pathway, the therapy helps reduce inflammation, control immune-mediated tissue damage, and improve patient quality of life. It is widely used in the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis, typically administered through subcutaneous injection or intravenous infusion depending on the formulation. One of its notable advantages is the convenient dosing schedule, which supports patient adherence in long-term treatment regimens. Recent market trends indicate growing interest in biologic immunology therapies, expansion of specialty pharmacy networks, and increasing clinical research focused on improving biologic treatment outcomes. Additionally, strategic collaborations between pharmaceutical companies and healthcare providers are strengthening patient access programs, further supporting demand for golimumab across major therapeutic markets.

Golimumab market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Golimumab Market Outlook

Market Key Insights

  • The Golimumab market is projected to grow from $16.8 billion in 2024 to $25.6 billion in 2034. This represents a CAGR of 4.3%, reflecting rising demand across Rheumatoid Arthritis Treatment, Psoriatic Arthritis Management, and Ankylosing Spondylitis Therapy.

  • This is a highly consolidated market with 2 key players, where Johnson & Johnson holds the dominant share.

  • U.S. and Germany are the top markets within the Golimumab market and are expected to observe the growth CAGR of 3.0% to 4.0% between 2024 and 2030.

  • Emerging markets including Brazil, Russia and India are expected to observe highest growth with CAGR ranging between 4.7% to 6.0%.

  • Industry players are pushing the adoption of transitions like Shift from hospital-based infusions to convenient self-administered biologic therapies for future years due to existing low growth of 4.3% ; but are also expected to invest $547 million by 2030.

  • The Golimumab market is set to add $8.8 billion between 2024 and 2034, with manufacturer targeting Home Care & Ambulatory Care Centers Application projected to gain a larger market share.

  • With

    rising prevalence of autoimmune disorders, and

    Advancements in Biologics, Golimumab market to expand 52% between 2024 and 2034.

golimumab market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Golimumab - Country Share Analysis

Opportunities in the Golimumab

Collaborations between pharmaceutical companies and research institutions are creating opportunities to expand golimumab’s clinical applications and extend its lifecycle. Ongoing research into additional autoimmune and inflammatory indications, including pediatric use, can unlock new patient segments. Partnerships also support advancements in formulation technologies, improving drug delivery and patient adherence. The rheumatology segment, particularly rheumatoid and psoriatic arthritis applications, is expected to benefit the most, as combination therapies and personalized treatment approaches evolve through collaborative innovation, strengthening golimumab’s competitive positioning.

Growth Opportunities in North America and Europe

North America represents the largest and most commercially mature market for golimumab, supported by high autoimmune disease prevalence, advanced healthcare infrastructure, and strong reimbursement frameworks. The U.S. dominates demand due to early adoption of biologic therapies and continuous expansion of approved indications. Top opportunities lie in lifecycle expansion and increased use in inflammatory bowel disease segments. However, competition is intense, with biosimilars and alternative TNF inhibitors driving pricing pressure. Payer-driven formulary decisions significantly influence demand patterns, often favoring cost-effective therapies. Despite this, innovation, specialty pharmacy distribution, and strong physician preference for proven biologics continue to sustain steady market growth and premium positioning.
Europe is the second-largest golimumab market, characterized by strong regulatory support and widespread biologics adoption, particularly in countries like Germany, France, and the UK. A key opportunity lies in expanding patient access through cost-efficient treatment models and increasing biologic penetration in autoimmune indications such as rheumatoid arthritis and ulcerative colitis. However, aggressive biosimilar competition and national tender systems significantly reduce pricing power, directly impacting revenue potential. Competition is further intensified by value-based procurement contracts that prioritize affordability over brand loyalty. While this limits margins, it increases treatment volumes, creating a volume-driven growth model for golimumab across European healthcare systems.

Market Dynamics and Supply Chain

01

Driver: Rising autoimmune disease prevalence alongside expanding biologic therapy adoption in chronic inflammatory care

One of the primary drivers of the golimumab market is also the simultaneous rise in autoimmune disease incidence and the accelerating adoption of biologic therapies. Globally, conditions such as rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel diseases are also increasing due to aging populations, lifestyle factors, and improved diagnostic capabilities, significantly expanding the patient pool requiring long-term immunomodulatory treatment. At the same time, there is also a strong industry shift toward biologics, particularly TNF-alfa inhibitors like golimumab, due to their targeted mechanisms and superior clinical outcomes compared to conventional therapies. This dual trend is also further reinforced by growing awareness and earlier diagnosis, which increases treatment initiation rates. Additionally, healthcare systems are also increasingly prioritizing biologics for chronic disease management, supported by favorable reimbursement frameworks and higher healthcare spending, thereby sustaining demand for advanced therapies such as golimumab.
Technological advancements in drug delivery systems and the expansion of golimumab into multiple therapeutic indications represent another key growth driver. Innovations such as subcutaneous self-administration and improved infusion formulations enhance patient convenience, adherence, and long-term treatment outcomes, making biologics more accessible outside hospital settings. Concurrently, ongoing clinical trials exploring new indications including pediatric autoimmune disorders and rare inflammatory conditions are also broadening the drug’s addressable market. This multi-indication strategy significantly increases lifecycle value by enabling the same biologic to serve diverse patient populations. Moreover, continuous R&D efforts focused on formulation improvements and precision-targeted therapies are also strengthening clinical efficacy profiles, positioning golimumab as a versatile and competitive option within the evolving biologics landscape.
02

Restraint: High biologic treatment costs coupled with restrictive reimbursement policies limit patient access

A major restraint in the golimumab market is the persistently high cost of biologic therapy combined with stringent reimbursement frameworks. Annual treatment costs can exceed tens of thousands of dollars, making affordability a key barrier, particularly in emerging markets and cost-sensitive healthcare systems. Payors often impose prior authorization requirements or mandate failure of cheaper therapies before approving golimumab, delaying treatment initiation and reducing eligible patient pools. For example, such restrictions can lower prescription volumes in public healthcare systems, directly constraining revenue growth. Additionally, high out-of-pocket costs discourage long-term adherence, reducing demand continuity and weakening lifecycle value. These combined financial barriers significantly limit market penetration despite strong clinical efficacy.
03

Opportunity: Expansion of golimumab adoption in emerging Asia-Pacific autoimmune disease markets and Growing demand for golimumab in ulcerative colitis treatment segment globally

Emerging markets in Asia-Pacific, particularly India, China, and Southeast Asia, present a significant growth opportunity for golimumab due to rising autoimmune disease diagnosis and improving healthcare infrastructure. Increasing healthcare expenditure and broader insurance coverage are enabling access to advanced biologics in urban centers. Additionally, growing physician awareness and patient education are accelerating early biologic intervention. Subcutaneous formulations of golimumab are expected to see the highest uptake in these regions due to ease of administration and reduced hospital dependency, making them suitable for expanding middle-class populations.
The ulcerative colitis segment represents a strong opportunity as prevalence rises globally and treatment paradigms shift toward biologics for moderate-to-severe cases. Golimumab’s approval for ulcerative colitis positions it well to capture patients who are unresponsive to conventional therapies. Increasing preference for long-acting TNF inhibitors with convenient dosing schedules further supports its adoption. The intravenous and subcutaneous forms targeting gastrointestinal indications are expected to grow, particularly in North America and Europe, where treatment guidelines increasingly recommend biologics earlier in the disease progression.
04

Challenge: Increasing biosimilar competition and therapeutic alternatives drive pricing pressure and market share erosion

The growing presence of biosimilars and alternative biologic classes is critically reshaping demand dynamics for golimumab. As patents expire across TNF-α inhibitors, lower-cost biosimilars enter the market at prices typically 10–35% lower, intensifying competition and forcing originator price reductions. This leads to significant revenue erosion, with price declines of up to 30–50% observed after biosimilar entry in some cases. Furthermore, physicians increasingly shift toward newer mechanisms such as interleukin inhibitors or JAK inhibitors, reducing reliance on traditional TNF inhibitors. For instance, treatment switching trends toward alternative biologics can dilute golimumab’s market share even in growing patient populations, ultimately slowing overall market expansion and altering prescribing behavior.

Supply Chain Landscape

1

Biologic Raw Materials

Thermo Fisher ScientificMerck KGaACytiva
2

Drug Manufacturing

Johnson & JohnsonJanssen Biotech Inc.
3

Distribution Networks

McKesson CorporationCencora Inc.Cardinal Health
4

End-User Applications

HospitalsRheumatology ClinicsSpecialty Pharmacies
Golimumab - Supply Chain

Use Cases of Golimumab in Rheumatoid Arthritis Treatment & Ankylosing Spondylitis Therapy

Rheumatoid Arthritis Treatment : Rheumatoid arthritis represents one of the largest therapeutic applications for golimumab, particularly in patients who show inadequate response to conventional disease modifying antirheumatic drugs. In this segment, subcutaneous golimumab formulations are most commonly prescribed due to their convenient monthly dosing and suitability for long term outpatient therapy. Rheumatology specialists and hospital clinics frequently recommend this therapy to suppress tumor necrosis factor activity, which plays a central role in inflammatory joint damage. By reducing inflammation and slowing structural joint deterioration, golimumab improves mobility and overall patient outcomes. The treatment is often used either as monotherapy or in combination with methotrexate, making it a widely integrated option in rheumatoid arthritis management strategies across hospitals and specialty rheumatology centers.
Psoriatic Arthritis Management : In psoriatic arthritis management, golimumab is widely utilized for controlling both joint inflammation and associated skin manifestations. The subcutaneous formulation is commonly used by dermatology and rheumatology specialists because it provides consistent systemic suppression of inflammatory pathways while offering patient friendly administration. Patients with moderate to severe disease often benefit from this therapy when conventional systemic treatments fail to provide adequate symptom control. Golimumab helps reduce joint swelling, stiffness, and psoriatic plaque progression, which contributes to improved physical function and quality of life. Specialty clinics and biologic therapy centers are major end users, as they closely monitor patient response and adjust treatment regimens for optimal long term disease control.
Ankylosing Spondylitis Therapy : Golimumab has become an important biologic therapy for ankylosing spondylitis, a chronic inflammatory disease primarily affecting the spine and sacroiliac joints. In this application, monthly subcutaneous golimumab injections are widely used due to their convenient dosing schedule and strong anti inflammatory activity. Rheumatologists prescribe the therapy for patients who do not respond adequately to nonsteroidal anti inflammatory drugs or other first line treatments. By inhibiting tumor necrosis factor driven inflammation, golimumab helps relieve spinal pain, reduce stiffness, and improve mobility in affected patients. Hospitals, rheumatology clinics, and specialty biologic treatment centers are the main end users, where regular monitoring ensures effective disease management and sustained therapeutic response.

Recent Developments

Recent developments in the golimumab market highlight a dual trend of lifecycle expansion and intensifying competition. The 2025 FDA approval for pediatric ulcerative colitis has expanded its addressable patient base, strengthening biologic therapy adoption in younger populations and boosting long-term demand potential. Simultaneously, rapid biosimilar launches across Europe and pending U.S. approvals are increasing price competition and improving access. This reflects a broader TNF inhibitor market shift toward cost optimization and wider accessibility, reshaping pricing strategies and competitive positioning within the autoimmune biologics landscape.

October 2025 : Johnson & Johnson received U.S. FDA approval for SIMPONI (golimumab) for pediatric ulcerative colitis, expanding its indication into younger patient populations and strengthening lifecycle value.
December 2024 : Johnson & Johnson submitted a supplemental Biologics License Application (sBLA) to the FDA seeking pediatric ulcerative colitis approval for golimumab, marking a strategic move toward indication expansion.

Impact of Industry Transitions on the Golimumab Market

As a core segment of the Pharmaceutical industry, the Golimumab market develops in line with broader industry shifts. Over recent years, transitions such as Shift from hospital-based infusions to convenient self-administered biologic therapies and Transition from traditional TNF inhibitors toward diversified immunology treatment portfolios have redefined priorities across the Pharmaceutical sector, influencing how the Golimumab market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Shift from hospital-based infusions to convenient self-administered biologic therapies

A notable industry transition for golimumab is the movement from hospital-based intravenous infusions to subcutaneous, self-administered biologic therapies. This shift reflects broader healthcare trends prioritizing patient convenience, reduced hospital burden, and cost efficiency. Golimumab’s subcutaneous format supports home-based care, aligning with post-pandemic healthcare delivery models. For example, reduced dependency on infusion centers lowers healthcare system costs while improving patient adherence, directly supporting stable demand. This transition also impacts the broader biologics industry by accelerating investment in user-friendly delivery devices and reshaping distribution channels toward retail and specialty pharmacies.
02

Transition from traditional TNF inhibitors toward diversified immunology treatment portfolios

The golimumab market is also shaped by a transition from reliance on traditional TNF inhibitors to more diversified immunology portfolios, including interleukin inhibitors and targeted therapies. Pharmaceutical companies are expanding beyond single-mechanism drugs to remain competitive in a rapidly evolving autoimmune treatment landscape. For instance, physicians increasingly prescribe newer biologics or small-molecule therapies based on patient-specific responses, reducing exclusive dependence on TNF inhibitors like golimumab. This shift intensifies competition and drives strategic repositioning, influencing revenue distribution across the immunology segment while encouraging innovation and combination therapy approaches across the pharmaceutical industry.